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Estrogen receptor ligands are important modulators of skin physiology and are involved in the control of normal
hair follicle cycling. Here, we have studied the effects of topically applied 17-b-estradiol on pathologic hair follicle
cycling as seen during chemotherapy-induced alopecia, one of the major unresolved problems of clinical oncology.
For this study we employed a well-established murine model that mimics chemotherapy-induced alopecia in
humans. For precisely quantifying the area of hair loss and hair regrowth in this model in vivo, we developed a
simple planimetric assay (dotmatrix planimetry). We show that topical 17-b-estradiol signiﬁcantly alters the cycling
response of murine follicles to cyclophosphamide, whereas the estrogen antagonist ICI 182.780 exerted no such
effects. Initially, topical 17-b-estradiol enhanced chemotherapy-induced alopecia signiﬁcantly by forcing the
follicles into the dystrophic catagen response pathway to hair follicle damage, whereas follicles treated by ICI
182.780 or vehicle shifted into the dystrophic anagen response pathway. Consequently, the regrowth of normally
pigmented hair shafts after chemotherapy-induced alopecia was signiﬁcantly accelerated in the 17-b-estradiol
treated group. Our data encourage one to explore topical estrogens as a potential stimulant for hair re-growth after
chemotherapy-induced alopecia.
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Although there are only few data on the molecular effects of
estrogens in human and rodent skin it is now appreciated
that estrogens can modulate, after binding to their nuclear
receptors (ER-a and ER-b), wound healing, skin aging,
cutaneous carcinogenesis, and hair growth (Calvin, 2000;
Conrad, et al, in press Gendimenico et al, 2002; Thornton,
2002). As well as the classical nuclear estrogen signaling
pathways, a number of nongenomic 17-b-estradiol (E2)
dependent signaling transductions like the mitogen-acti-
vated protein kinase cascade are now known to be involved
in a variety of biologic processes (Collins and Webb, 1999).
Furthermore, in the absence of E2, ER-a and ER-b can be
activated through phosphorylation by protein kinase A and
C, extracellular signals such as peptide growth factors,
cytokines, neurotransmitters, and cell cycle regulators
(Chalbos et al, 1994; Nilsson et al, 2001). With respect to
the skin these mechanisms still remain obscure. As for hair
growth, it has been shown that the prototypic estrogen E2
inhibits, whereas the ER antagonist ICI 182.780 stimulates
hair growth and that gonadectomy results in a profound and
rapid telogen to anagen transition. The authors interpreted
this E2 effect by an inhibition of the telogen-to-anagen
transition of the hair follicle (HF) cycle (Oh and Smart, 1996;
Smart et al, 1999; Chanda et al, 2000; Move´rare et al, 2002).
Species-specific differences in HF responses to estrogens
are briefly summarized in Table I.
As the clinically most important human hair growth
disorders are based on abnormalities of HF cycling (Paus,
1996; Paus and Cotsarelis, 1999; Stenn and Paus, 2001),
we have examined in this study, the effects of exogenous
ER ligands on pathologic HF-cycling in mice. Chemother-
apy-induced alopecia (CIA) was selected as a model, since
it allows analysis of the damage response of the HF and
how it is affected by a given test agent (Paus et al, 1994,
1996; Slominski et al, 1996; Peters et al, 2001). In addition,
CIA remains one of the most severe problems of clinical
oncology that leaves a psychologically disastrous impact on
affected patients and their social environment, for which a
truly satisfactory remedy remains to be developed in clinical
practice (de Vita et al, 2001; Bronner and Hood, 1983;
Kiebert et al, 1990).
Hypothesizing that a systematic analysis of estrogen
effects in this model may identify new principles and
options for the management of CIA, we used a previously
described, well-established mouse model of CIA in C57BL/
6 mice with all back skin HF in depilation-induced anagen VI
(Paus et al, 1994, 1996; Maurer et al, 1997; Schilli et al,
1998; Peters et al, 2001). This model strikingly reproduces
the response of the human HF to cyclophosphamide tre-
Abbreviations: CIA, chemotherapy-induced alopecia; E2,
17-b-estradiol; ER, estrogen receptor; ER-a, estrogen
receptor type a; ER-b, estrogen receptor type b; HF, hair
follicle; ICI 182.780, Imperial Chemical Industries com-
pound no. 182.780 (¼pure ER antagonist).
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atment under clinical conditions (Braun-Falco, 1961; Paus
et al, 1994). In order to quantify accurately the area of initial
hair loss and subsequent hair regrowth macroscopically
and in vivo, we developed a simple planimetric assay
(dotmatrix planimetry), which invites multiple uses in future
hair research (see Materials and Methods). HF cycling was
assessed by quantitative histomorphometry (Mu¨ller-Ro¨ver
et al, 2001). The degree of HF dystrophy, as evident, e.g.,
from the level and quality of HF pigmentary abnormalities
(Paus et al, 1994; Slominski et al, 1996; Tobin et al, 1998),
was evaluated using recently defined morphologic guide-
lines for classifying HF dystrophy (Mu¨ller-Ro¨ver et al, 2002).
In this mouse model of CIA, we had previously
established that the HF response to and recovery from
chemical damage after cytostatic therapy can be distin-
guished into the ‘‘dystrophic anagen’’ and the ‘‘dystrophic
catagen pathway’’, which determine the onset, the degree,
and the quality of the initial alopecia after cytostatic drug
administration and the subsequent re-growth of the hair
shafts (Paus et al, 1994). If the dystrophic anagen pathway
is chosen, the damaged HF actually remains longer in
anagen than is normally seen, yet produces only function-
ally impaired, depigmented hair shafts during this recovery
within the same anagen phase. If instead, the dystrophic
catagen pathway is chosen, anagen is immediately termi-
nated, followed by a dystrophic catagen and a remarkable
shortened telogen phase, with the ability to reconstruct a
new, fully functional hair shaft factory and HF pigmentary
unit (i.e., the anagen hair bulb) at maximal speed. Conse-
quently, HF that choose this damage response pathway,
initially, exhibit the most severe and fastest alopecia, yet
also have the fastest regrowth of normally pigmented hair
shafts during this maximally accelerated secondary recov-
ery phase. Therefore, in addition to assessing the macro-
scopic effects of these agents on CIA and hair shaft
regrowth in this model, we wished to analyze specifically,
whether treatment of cyclophosphamide-damaged HF with
E2 or the ER antagonist ICI 182.720 favored the dystrophic
anagen or the dystrophic catagen response pathway to
chemical HF damage.
Results and Discussion
Topical E2 accelerates the development of alopecia
after chemotherapy Initially, we evaluated how exogen-
ous, topically applied E2 influences the development of
alopecia after chemotherapy. Five days after CIA induction
(i.e., 14 d after anagen induction by depilation), mice that
had been treated with the vehicle alone or with the ER
antagonist ICI 182.780 showed marked anagen effluvium
with circular or irregularly shaped alopecic areas. In cont-
rast, E2-treated animals exhibited large and confluent areas
of complete baldness (Fig 1), and the area of alopecic back
skin was significantly larger (pp0.001) in E2-treated animals
than in the other groups (Fig 2). On day 16 after anagen
induction there were no macroscopic differences between
the three groups and all animals displayed complete
alopecia. A time course is given in Fig 3.
E2 promotes the dystrophic catagen HF response
pathway to damage Quantitative histomorphometry revealed
that E2-treated animals predominantly showed HF in dys-
trophic catagen stages (Fig 4). These were character-
ized by shortened, catagen-like HF and abnormally dilated
hair canals that did not contain hair shafts, along with
pigmentary abnormalities such as melanin incontinence and
clumping of melanosomes. In contrast to the E2-treated
group, vehicle or ICI 182.780-treated mice exhibited
predominantly dystrophic anagen follicles 14 d after
depilation (Fig 4). These were characterized by clumped
melanin globules, and a reduction in size of the dermal
papilla below one-third of the hair bulb diameter. Figure 5(A)
illustrates E2-treated follicles that are mainly in mid-
dystrophic catagen, whereas Fig 5(B) shows E2 treated,
mid to late dystrophic catagen follicles, 14 d after depilation.
As seen in Fig 5(C,D), vehicle-treated follicles display strong
to severe dystrophic anagen, following recently defined
guidelines for assessing the degree of HF dystrophy (Mu¨ller-
Ro¨ver et al, 2002). Therefore, E2 has a catagen-promoting
effect and interacts with the two defined pathways of HF
response to chemical damage by strongly favoring the
dystrophic catagen over the dystrophic anagen pathway
(Fig 6) (Paus et al, 1994). The catagen-promoting properties
of E2 seen in this CIA model is perfectly in line with our
recent identification of topical E2 as a potent catagen
inducer. In a separate study we observed that exogenous
applied E2, if compared with ICI 182.780 or control,
significantly accelerated catagen development in anagen
HF during normal murine hair cycling. Between the control
and the ICI 182.780-treated group no significant differences
were observed1.
Table I. Species-speciﬁc differences of estrogens on hair growth
Species Reported effect Reference
Mouse Spontaneous hair growth is inhibited in pregnant and lactating mice Fraser and Nay (1953)
Rat Hair growth waves in female rats lag behind males Emmens (1942); Johnson (1958)
Guinea pig Local inhibition of hair growth in guinea pigs receiving topical
applications of estradiol
Whitaker (1956); Jackson and Ebling (1972)
Dog Estrogen inhibits hair growth in dogs Gardner and De Vita (1940)
Human Estrogen prolongs the anagen phase of human scalp hair Schumacher-Stock (1981)
1Ohnemus U, Unalan M, Handjiski B, Nakamura M, Liotiri S,
Conrad F, Bettermann A, Paus R. Estrogen effects on murine and
human hair follicle cycling. JID 121:824, 2003
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The estrogen receptor antagonist ICI 182.780 failed to
protect from alopecia and the animals showed the same
extent of CIA and HF dystrophy as the vehicle-treated
controls (Fig 4). E2 shares this property with other nuclear
hormone receptor ligands, such as dexamethasone and
calcitriol (Paus et al, 1996; Schilli et al, 1998) as well as with
PTH/PTHPrP receptor agonists (Peters et al, 2001), all of
which have in common the fact that they fail to protect from
CIA in this mouse model and, moreover, accelerate
pathologic cyclophosphamide-induced catagen, thus wor-
sening the initial alopecia after cyclophosphamide injection
(Paus et al, 1994). This further supports our previous
postulate that catagen-promoting substances also promote
the dystrophic catagen pathway whenever the HF is
damaged (Paus et al, 1994). As the degree of dystrophic
catagen development during CIA is proportional to the
cyclophosphamide dose employed and therefore to the
degree of chemical damage as well as to the amount of
apoptosis induced as a consequence, one may speculate
that both apoptosis-driven events (catagen, CIA) promote
each other (Paus et al, 1994, 1996; Schilli et al, 1998).
Topical E2 accelerates hair re-growth after chemother-
apy Based on our previous findings (Fig 6), one would
expect that promotion of the dystrophic catagen pathway
also promotes HF recovery and the regrowth of fully
functional, normally pigmented hair shafts. Therefore, the
chemotherapy experiment was extended and the influence
of E2 on the recovery period was investigated, 28 to 32 d
after chemotherapy. Vehicle- or ICI 182.780-treated animals
showed only sparse hair regrowth. About 25 to 30% of the
Figure2
Dotmatrix analysis of CIA in C57BL/6 mice on day 14 after
depilation. CYP injection 120 mg per kg on day 9 after anagen
induction. The graph shows the percentage of animals with alopecic
back skin. E2 treatment promotes significant enhancement of CYP-
induced alopecia, whereas ICI 182.780 fails to protect from it. Given are
the mean  1 SEM of pooled data from three identical experiments,
n¼ 90, representing a total of 30 animals per group. Level of
significance compared with control: pp0.05; pp0.01; pp0.001.
Figure 1
Macroscopic effects (alopecia and skin color changes) after CYP
injection in depilated murine back skin. Representative mice backs
are shown. Left column: day 14 after depilation (5 d after CYP injection).
Note that mice treated with E2 show big areas of bald back skin and in
areas without maximal alopecia a translucent, grayish skin color.
Vehicle or ICI 182.780-treated animals predominantly exert isolated and
small circular areas with complete baldness. Right column: day 32 after
depilation (23 d after CYP injection). Follicles have entered a new cycle
with a synchronized wave of anagen follicles (secondary recovery). E2-
treated animals show full recovery from CIA with enhanced and better
pigmented hair regrowth compared with the control and the ICI
182.780-treated group. The figure also demonstrates that alopecia was
more severe in the neck than in the tail area of murine back skin.
ESTROGEN MODULATION OF CIA 9122 : 1 JANUARY 2004
back skin area was markedly pigmented, indicating the
regrowth of pigmented hair shafts during the subsequent
anagen phase (Figs 1 and 7). In contrast, E2-treated animals
revealed a significantly larger area of hair regrowth (Figs 1
and 7). The time course of hair shaft regrowth is given in Fig
3. Histomorphometry confirmed that E2-treated follicles had
already entered into secondary recovery by showing a
predominance of anagen VI HF, whereas the two other
groups exhibited large percentages of late catagen and
early anagen stages (Fig 8). Morphologically the recon-
structed anagen VI HF of E2-treated mice were of normal
appearance, with only a few ectopic melanin granula visible
in the dermis, as a morphologic record of the damage the
preceding anagen HF and its pigmentary unit had suffered
(Fig 8). During the observation time neither significant
alterations or advances of hair regrowth nor improvement
in the regrowth of well-pigmented hair shafts after CIA were
apparent under ICI 182.780 treatment (Fig 8).
Figure 4
Morphometric analysis of CYP-induced dystrophic anagen versus
dystrophic catagen on day 14 postdepilation, i.e., 5 d after single
dose of 120 mg CYP per kg. None of the compounds protects from
HF dystrophy caused by chemotherapy. Compared with the control
and the ICI 182.780-treated groups, mice treated with E2 display
significantly more follicles in dystrophic catagen and significantly less
follicles in dystrophic anagen. Given are the mean  1 SEM, n¼39,
representing a total of 13 animals per group. Level of significance
compared with control: pp0.05; pp0.01.
Figure5
Representative histopathology on day 14 after depilation, i.e., 5 d
after CYP injection. Sections impressively display pigmentation
disorders, which were induced by CYP. (A,B) E2-treated group; (C,D)
vehicle control. (A,B) Show mid-to-late dystrophic catagen follicles as
mainly seen in the E2-treated CIA skin. Arrows indicate clumping of
melanin and abnormally dilated hair canals not containing a hair shaft.
Ectopic distribution of melanin as a sign of dystrophy can be seen in
(C). (C,D) Sections of severe dystrophic anagen follicles, typical for the
vehicle-treated control and the ICI 182.780-treated group. ap, arrector
pili muscle; bv, blood vessel; d, dermis; dp, dermal papilla; ep,
epithelium; HS, hair shaft; inf, infundibulum; m, hair matrix; ORS, outer
root sheath; pc, panniculus carnosus muscle; sc, subcutis; sg,
sebaceous gland; tes, tailing epithelial strand.
Figure 3
Time course of visible alopecia and hair re-growth from day 9 until
day 32 after anagen induction. The graph shows the percentage of
back skin areas with hair shafts over the time from day 9 until day 32
after anagen induction, assessed by dotmatrix planimetry. It demon-
strates that E2 significantly accelerates the course of alopecia induced
by CYP injection from day 9 until day 16 compared with control or ICI
182.780-treated animals. From day 22 until day 32 hair shaft regrowth
is accelerated under E2 treatment, compared with vehicle and ICI
182.780-treated animals. There are significant differences between
animals treated with ICI 182.780 and E2, as well as between control
and E2-treated animals on day 28. On day 32 the differences are only
significant between ICI 182.780- and E2-treated animals. Given are the
mean  1 SEM of pooled data from three identical experiments. Day 9:
n¼129, representing a total of 43 animals per group. Day 14: n¼90,
representing a total of 30 animals per group. Day 16, 22, 24, 28, and 32:
n¼51, representing a total of 17 animals per group. Level of
significance compared with control: pp0.05; pp0.01; pp0.001.
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This supports the concept that follicles that respond to
chemotherapy by entering dystrophic anagen retain their
hair shafts longer but have greater difficulties in recovering
from chemical damage than follicles entering dystrophic
catagen, and therefore promoting secondary recovery (Fig
6) (Paus et al, 1994, 1996; Schilli et al, 1998; Peters et al,
2001). The latter rapidly run through a dystrophic catagen
and a dramatically shortened telogen phase, and produce
new hair shafts only during the following hair cycle. This
secondary recovery phase occurs much earlier than in
dystrophic anagen HF and generates mainly healthier, well-
pigmented hair shafts (Fig 6). A previous report that topical
E2 arrests normal murine back skin HF in the telogen stage
of the hair cycle and that only telogen HF express ER (Oh
and Smart, 1996), would have suggested that E2 also
significantly retards the re-growth of normal anagen HF
from dystrophic catagen HF. The fact that the opposite was
seen suggests, however, that in contrast to previously
voiced concepts (Oh and Smart, 1996; Smart et al, 1999)
anagen VI HF are quite responsive to ER stimulation and are
thereby induced to enter catagen prematurely. This is in line
with our recent finding that E2 is indeed a potent catagen
inducer in normal murine HF and that late anagen VI and
catagen HF in C57BL/6 mice do express ER-a and ER-b on
the gene and protein level.1
Although the effects exerted by E2 observed in the
current CIA model resemble those of other steroid
hormones, namely glucocorticosteroids (Paus et al, 1994)
and calcitriol (Paus et al, 1996; Schilli et al, 1998), the
underlying mechanisms which they are controlled remain to
be elucidated. The complex molecular signaling pathways
of the two estrogen receptors ER a and ER b, their intricate
interactions with agonists and antagonists, multiple signal
cross-talk mechanisms, and a plethora of molecules
involved in ER signaling (coactivation, corepression) (Paech
et al, 1997; Nilsson and Gustafsson, 2000; Nilsson et al,
2001; Thornton, 2002), make it a dauntingly difficult task to
determine which cellular responses to ER ligands within the
HF or its direct vicinity are responsible for the observed hair
cycle-modulatory effects of E2. Our data, however, suggest
that topically applied ER agonists could become an
effective tool in the control of pathologic HF cycling and
Figure 6
Dystrophic pathways (anagen and cata-
gen) of CIA. Schematic representation of
the two different pathways of CYP-in-
duced HF dystrophy: dystrophic anagen
and dystrophic catagen pathway (dysA
and dysC). Size of the black flashes
indicate the degree of follicle damage.
Vehicle control (acetone) and ICI 182.780
promote the dysA pathway, E2 promotes
the dysC pathway. During the dysA path-
way the hair shaft is shed and the follicle
undergoes a primary recovery. The follicle
is not fully recovered before it undergoes a
complete catagen–telogen transition to
enter the final secondary recovery stage.
During the dysC pathway, follicles are
severely damaged and enter directly into
dysC and a shortened dystrophic telogen.
Without passing through the primary
recovery the follicles enter directly into
the complete secondary recovery stage
with normal pigmented hair shafts (mod-
ified after Muller-Rover et al, 2002).
Figure 7
Dotmatrix analysis of recovery from CIA and regrowth of normal
pigmented hair shafts 28 d after anagen induction, i.e., 19 d after
CYP injection. The panel shows that E2 significantly accelerates
recovery from CIA and regrowth of normal pigmented hair shafts
compared with control or ICI 182.780-treated animals. Given are the
mean  1 SEM, n¼51, representing a total of 17 animals per group.
Level of significance compared with control: pp0.05; pp0.01.
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be used, whenever desired, for premature catagen induc-
tion. Additionally, estrogens deserve to be fully explored as
potential stimulators of hair regrowth after CIA in humans.
Materials and Methods
Animals Six to 9 wk old syngenic female C57BL/6 mice (15–20g)
were purchased from Charles River (Sulzfeld, Germany) and housed
in community cages with 12 h light periods at the Charite´ Animal
Facilities, Campus Virchow Hospital. They were fed water and
mouse chow ad libitum. All experiments were performed in accor-
dance with applicable German laws on the use of laboratory animals.
CIA model and E2 or ICI 182.780 treatment Mice with all back
skin HF in telogen, as recognized by their pink skin color, were
induced to enter active hair growth (anagen) by hair shaft
depilation, as described in detail before (Paus et al, 1990). CIA
was generated as previously described (Paus et al, 1994). Briefly, in
three identical, independent experiments with a total of 86 test and
43 control animals three groups of mice received intraperitoneally a
single dose of 120 mg per kg cyclophosphamide (ENDOXAN,
ASTA-Medica, Frankfurt, Germany) in 0.9% NaCl 9 d after
depilation. Starting 1 d before the cyclophosphamide injection,
mice were treated topically with 10 nmol E2 or with ICI 182.780 (E2
from Schering AG, Berlin, Germany, gift of Dr A. Menrad, ICI
182.780 from ASTRA ZENECA, Wedel, Germany) once daily for 5 d.
Acetone, used as vehicle, was applied as the control. Individual
mice from the test and control groups were euthanized randomly
for histology at selected time points. On day 32, all remaining mice
were euthanized and back skin was embedded as described
previously (Paus et al, 1999). Macroscopic and microscopic
analyses of the test and control mice were performed between
day 10 and 32 after anagen induction.
Macroscopic analysis by ‘‘dotmatrix planimetry’’ For the
accurate, quantitative assessment of cyclophosphamide-induced
alopecia and hair regrowth a new planimetric assay (dotmatrix
planimetry) was developed. Under a ketamine anesthesia, mouse
back skin is clipped with electric clippers and photos are taken
from the back skin. A transparency (e.g., for overhead projectors) is
placed on each developed photo and the appropriate areas (e.g.,
of hair loss or hair regrowth) are demarcated on the foil. Afterwards
a printed sheet with a defined, uniform dot pattern (i.e., the
dotmatrix) is placed under the transparent foil to quantify the
percentage of the marked area relative to the total reference area,
and is examined under a desk monitor-projector combination
(Reflecta Diamantor AFM, MC Germany). The encircled underlying
dots are counted and related to the dot count of the whole back
skin area. Measuring areas by counting dots is superior to other
possible methods due to the nongeometrically, irregularly shaped,
encircled skin areas.
Microscopic analysis by quantitative histomorphometry After
cyclophosphamide injection, quantitative histomorphometry was
performed at different time points, i.e., HF were classified
according to their hair cycle stage and signs of follicle dystrophy
(Paus et al, 1994, 1996; Tobin et al, 1998; Mu¨ller-Ro¨ver et al, 2001,
2002). The time points of skin harvesting and the number of
animals analyzed for performing histomorphometry are given in the
figure legends. Morphometry was performed on Giemsa-stained 8
mm formalin-fixed, paraffin-embedded sections, which were taken
from defined back skin regions. A minimum of 50 back skin HF
were analyzed for each test and control mouse.
Statistical analysis Data derived from identical experiments were
pooled and mean values were calculated. With the statistical
analysis software SPSS (SPSS Inc., Chicago, Illinois), significance
was assessed with the Mann–Whitney U test for unpaired samples
combined with Monte-Carlo calculation for accuracy. pp0.05 were
accepted as significant.
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